ABVC BioPharma (ABVC) News Today $0.54 -0.03 (-5.48%) (As of 12:45 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational MilestonesNovember 14, 2024 | finance.yahoo.comRAKUS Co., Ltd. Reports Strong Growth in 2024November 14, 2024 | msn.comABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic PartnersOctober 22, 2024 | globenewswire.comABVC BioPharma (NASDAQ:ABVC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsAugust 15, 2024 | globenewswire.comABVC BioPharma's CEO Discusses New Drug Development and AI IntegrationJuly 19, 2024 | finance.yahoo.comImmunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50MMay 24, 2024 | finance.yahoo.comABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24MMay 22, 2024 | finance.yahoo.comABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024May 17, 2024 | investorplace.comPromising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50MMay 15, 2024 | finance.yahoo.comCombination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MMay 9, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC)April 26, 2024 | finance.yahoo.comABVC BioPharma inks licensing deal for cancer drugApril 18, 2024 | investing.comABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | finanznachrichten.deAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | globenewswire.comABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404April 17, 2024 | markets.businessinsider.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | finance.yahoo.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MApril 10, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 28, 2024 | finanznachrichten.deWhy ABVC BioPharma Stock Is Up TodayMarch 27, 2024 | msn.comABVC Announces Global Licensing Deal With ForSeeCon Eye For VitargusMarch 26, 2024 | markets.businessinsider.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 26, 2024 | globenewswire.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsMarch 21, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo FinanceMarch 19, 2024 | ca.finance.yahoo.comABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineMarch 19, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | finanznachrichten.deABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | globenewswire.comABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsFebruary 27, 2024 | finance.yahoo.comABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | finanznachrichten.deABVC Signes Agreement To License Its 'Know-How' To SPIFebruary 15, 2024 | markets.businessinsider.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | finance.yahoo.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | finanznachrichten.deABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDFebruary 12, 2024 | markets.businessinsider.comABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | finance.yahoo.comABVC BioPharma Conducts Private Equity and Warrants SaleFebruary 9, 2024 | msn.comABVC BioPharma Expands Footprint with Strategic Land AcquisitionsFebruary 9, 2024 | msn.comLooking Into ABVC BioPharma's Recent Short InterestJanuary 25, 2024 | benzinga.comABVC BioPharma files to sell 10.4M shares for holdersJanuary 12, 2024 | msn.comWhy Is Plant-Based Medications-Focused ABVC BioPharma Stock Trading Higher Today?January 3, 2024 | msn.comABVC BioPharma Reports Milestone Payment From From AiBtl BioPharma; AiBtl Becomes SubsidiaryJanuary 3, 2024 | markets.businessinsider.comABVC BioPharma Shares Jump 73% After Milestone PaymentJanuary 3, 2024 | marketwatch.comABVC Biopharma and unit receive $460M as first milestone payment; shares jumpJanuary 3, 2024 | msn.comABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyDecember 7, 2023 | finance.yahoo.comABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsDecember 5, 2023 | finance.yahoo.comABVC BioPharma, Inc.: ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 21, 2023 | finanznachrichten.deABVC BioPharma Shares Rise 11% After U.S. Patent for ADHD TreatmentNovember 21, 2023 | marketwatch.comABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 21, 2023 | finance.yahoo.comABVC BioPharma Enters Into Global LIcensing Agreement With AiBtlNovember 16, 2023 | markets.businessinsider.com Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide ABVC Media Mentions By Week ABVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABVC News Sentiment▼0.730.47▲Average Medical News Sentiment ABVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABVC Articles This Week▼10▲ABVC Articles Average Week Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RenovoRx News Today Daré Bioscience News Today Tonix Pharmaceuticals News Today DURECT News Today Longeveron News Today BioLineRx News Today MiNK Therapeutics News Today Natural Alternatives International News Today Pluri News Today Marker Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABVC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
